#ctmx
Latest news and interesting information about ctmx.
Wolfe Research Initiates CytomX Stock with Outperform
Wolfe Research initiated CytomX Therapeutics (CTMX) with an outperform rating and $3.50 target. Varseta-M shows promise in colorectal cancer.
...
